Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Corneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing
progression of both keratoconus and corneal ectasia after surgery, as well as possibly
decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in
which the epithelium is not removed has been proposed to offer a number of advantages over
traditional crosslinking including an increased safety profile by reducing the risk for
infection and scarring, faster visual recovery and improved patient comfort in the early
postoperative healing period.